FDA approves combination hepatitis C treatment
BY Advocate.com Editors
December 06 2002 12:00 AM ET
The Food and Drug Administration on Tuesday approved Roche's hepatitis C treatment that combines the company's drug Pegasys, an interferon-alpha compound approved separately by the FDA in October, and the antiviral drug ribavirin, marketed by Roche as Copegus. Combining inteferon and ribavirin has been the traditional hepatitis C treatment for several years, but previously available forms of interferon-alpha had to be injected three times per week. Pegasys, a long-lasting form of interferon, is injected only once a week. The FDA approved Roche's combination treatment after reviewing data that showed the once-a-week injections, when coupled with Copegus, were more effective in lowering hepatitis C viral levels than the standard combination therapy. Roche also is currently testing Pegasys for the possible treatment of hepatitis B.
- WATCH: The Best of LGBT Chorus Holiday Music
- Op-ed: Two and a Half Men Introduces Trans Character, Manages to Stay Respectful
- PHOTOS: We Asked The Stars, Who Is Your Hero?
- WATCH: Obama Invokes LGBT Rights in Mandela Eulogy
- Salvation Army 'Does Not Consider Homosexual Orientation a Sin'
- New Gay U.S. Ambassador Meets With Dominican President
- Women Emily Rios' Lesbian Character on The Bridge Upped to Series Regular 44 min 40 sec ago
- Media Russia Expert to Offer Political Commentary During Olympics 1 hour 36 min ago
- Travel In-Flight Cellphone Conversations: Dream or Nightmare? 1 hour 43 min ago
- Politics New Gay U.S. Ambassador Meets With Dominican President 2 hours 24 min ago
- Latest News NBC To Spotlight Russia’s Human Rights Abuses During Olympics 6:11 PM
- Couples/Personal Finances The Financial Effects of DOMA: Filing Taxes 5:56 PM
- Couples/Personal Finances Examining Employee Benefits in the Wake of DOMA’s Overturn 5:38 PM